A Randomized, Controlled, Evaluator-blinded, Multi-center, Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection

Trial Profile

A Randomized, Controlled, Evaluator-blinded, Multi-center, Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2018

At a glance

  • Drugs LYS-228 (Primary)
  • Indications Urinary tract infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2018 Planned End Date changed from 23 Dec 2018 to 1 Apr 2019.
    • 05 Mar 2018 Planned primary completion date changed from 23 Dec 2018 to 1 Apr 2019.
    • 05 Mar 2018 Planned initiation date changed from 18 Jan 2018 to 22 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top